beta

GNMX

Aevi Genomic Medicine, Inc.

Gnmx

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

Actual EPS
Consensus EPS
Estimated EPS
Number of Estimates
EPS Surprise

Stats

Summary

Aevi Genomic Medicine, Inc. is a clinical stage biopharmaceutical company, which engages in finding treatments for rare and orphan diseases. Its research and development efforts leverage an internal genomics platform and an ongoing collaboration with the Center for Applied Genomics (CAG) at The Children's Hospital of Philadelphia (CHOP). The company was founded by Andrew Leonard Pearlman on January 27, 2000 and is headquartered in Wayne, PA.

Market Cap: 8.48 Million

Primary Exchange: NASDAQ

Website: http://www.aevigenomics.com

Shares Outstanding: 64.8 Million

Float: 41.4 Million

Dividend: (%)

Beta: 1.15498030661685

Sector: Health Technology

Industry: Biotechnology

Short Interest (Jan 12, 2018): 238 Thousand

Ethical Flags

Animal testing

Longest drawdown: 1710 trading days

From: 2015-09-18 To: 2019-11-12

Lowest Point:

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
Data provided by IEX Cloud